| Drug Name |
Nefazodone |
| Drug ID |
BADD_D01546 |
| Description |
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. |
| Indications and Usage |
For the treatment of depression. |
| Marketing Status |
approved; withdrawn |
| ATC Code |
N06AX06 |
| DrugBank ID |
DB01149
|
| KEGG ID |
D08257
|
| MeSH ID |
C051752
|
| PubChem ID |
4449
|
| TTD Drug ID |
D0X7DE
|
| NDC Product Code |
Not Available |
| UNII |
59H4FCV1TF
|
| Synonyms |
nefazodone | Serzone | Dutonin | Nefadar | nefazodone hydrochloride | Lin-Nefazodone | Menfazona | Rulivan | Apo-Nefazodone |
